BAY 737977Alternative Names: BAY 73-7977
Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 22 Mar 2006 Phase-I clinical trials in Diabetes mellitus in Germany (unspecified route)